8-K: Gossamer Bio Announces Positive Phase 3 Trial Update and First Quarter 2025 Financial Results

Gossamer Bio reports progress on its Phase 3 PROSERA study for PAH, anticipates enrollment completion in early June, and announces Q1 2025 financial results.

Summary

• Gossamer Bio announced its first quarter 2025 financial results and provided a business update on May 15, 2025.
• New patient screening for the Phase 3 PROSERA study in PAH has closed, with enrollment completion expected in early June.
• Topline results from the PROSERA Phase 3 study are expected in February 2026.
• The company expects to activate clinical sites for the Phase 3 SERANATA study in PH-ILD in the fourth quarter of 2025.
• Cash, cash equivalents, and marketable securities totaled $257.9 million as of March 31, 2025.
• Revenue from the collaboration with Chiesi was $9.9 million for the quarter ended March 31, 2025, including $6.6 million of cost reimbursement revenue.
• Research and Development expenses were $38.0 million for the quarter ended March 31, 2025.
• General and Administrative expenses were $8.7 million for the quarter ended March 31, 2025.
• Net loss for the quarter ended March 31, 2025, was $36.6 million, or $0.16 basic net loss per share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, strong cash position, and collaboration revenue. However, the net loss and increased R&D expenses temper the overall sentiment.

Positives

• The PROSERA Phase 3 study is nearing full enrollment, indicating strong progress in the PAH program.
• Alignment with global regulatory authorities (FDA and EMA) has been achieved for the SERANATA study design, de-risking the PH-ILD program.
• The company's cash runway extends into the first half of 2027, providing financial stability.
• Revenue from the Chiesi collaboration contributes to the company's financial resources.

Negatives

• The company reported a net loss of $36.6 million for the first quarter of 2025.
• Research and development expenses increased to $38.0 million compared to $32.4 million for the same period in 2024.

Risks

• The success of clinical trials is subject to inherent risks and uncertainties.
• Regulatory approvals are not guaranteed and may be delayed.
• Unexpected adverse side effects or inadequate efficacy of seralutinib could limit its development and commercialization.
• The company's dependence on third parties for manufacturing and testing poses a risk.
• Unstable market and economic conditions could adversely affect the company's business and financial condition.

Future Outlook

Gossamer Bio expects its current cash, cash equivalents, and marketable securities to fund operating and capital expenditures into the first half of 2027. The company anticipates announcing topline results from the PROSERA Phase 3 study in February 2026 and activating clinical sites for the SERANATA Phase 3 study in the fourth quarter of 2025.

Management Comments

• Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer Bio, stated that the company is just weeks away from fully enrolling the PROSERA Phase 3 Study in PAH.
• He also expressed optimism for meaningful results from the PROSERA study.
• Chief Medical Officer Dr. Richard Aranda highlighted the clinical trial design for the Phase 3 SERANATA Study in PH-ILD as a landmark moment in addressing unmet patient need.

Industry Context

Gossamer Bio is focused on developing seralutinib for pulmonary hypertension, a competitive space with significant unmet need. The company's progress in Phase 3 trials and collaboration with Chiesi Group positions it as a key player in the pulmonary hypertension market.

Comparison to Industry Standards

• The PROSERA study's design, including the use of enrichment criteria based on the REVEAL Lite 2 Risk Score, is similar to strategies employed by other companies in PAH clinical trials to improve the likelihood of demonstrating a treatment effect.
• The target enrollment of over 350 patients in the PROSERA study is comparable to other Phase 3 PAH trials, such as those conducted by Actelion (now part of Johnson & Johnson) for drugs like Tracleer and Opsumit.
• The primary endpoint of change in six-minute walk distance (6MWD) is a standard measure used in PAH clinical trials and is consistent with regulatory guidelines for drug approval in this indication.

Stakeholder Impact

• Positive impact on patients with PAH and PH-ILD if seralutinib proves to be an effective treatment.
• Potential benefits for shareholders through increased company value if clinical trials are successful and the drug is commercialized.
• Continued employment and research opportunities for employees.
• Collaboration with Chiesi Group benefits both companies through shared development costs and potential revenue.

Next Steps

• Complete enrollment of the PROSERA Phase 3 study in early June.
• Activate clinical sites for the SERANATA Phase 3 study in the fourth quarter of 2025.
• Announce topline results from the PROSERA Phase 3 study in February 2026.

Key Dates

Keywords

seralutinib, pulmonary hypertension, PAH, PH-ILD, PROSERA, SERANATA, clinical trial, Gossamer Bio, financial results